NextCell Pharma AB
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
NXTCL | ST
Overview
Corporate Details
- ISIN(s):
- SE0009723125 (+1 more)
- LEI:
- 549300PBFGB5JYKXGA45
- Country:
- Sweden
- Address:
- Hälsovägen 7, 141 57 Huddinge
- Website:
- https://nextcellpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
NextCell Pharma AB is a biopharmaceutical company specializing in the development of novel stromal cell therapies for autoimmune and inflammatory diseases. The company's lead drug candidate, ProTrans, is an allogeneic, off-the-shelf cell therapy product based on its patented selection algorithm, primarily targeting the treatment of type 1 diabetes. In addition to its therapeutic pipeline, NextCell operates a biobank for the long-term storage of stem cells, including adipose (fat) tissue-derived cells. The company engages in strategic collaborations, notably with FUJIFILM Biosciences, and invests in adjacent technologies such as CAR-T to strengthen its position in the advanced therapy medicinal products sector.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all NextCell Pharma AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for NextCell Pharma AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
